^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cotelet (tagitanlimab)

    i
    Other names: HBM9167, A 167, KL A167, KLA167, A167, KL-A167, A-167, HBM 9167, HBM-9167
    Associations

    News

    Trials
    Company:
    Akesobio, Harbour BioMed, Sichuan Kelun Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    SKB500-II-02: SKB500 Combinations in Patients With Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • etoposide IV • Cotelet (tagitanlimab)
    14d
    Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, West China Hospital
    New P2 trial • IO biomarker
    |
    Trodelvy (sacituzumab govitecan-hziy) • Cotelet (tagitanlimab)
    1m
    Recent highlights and breakthroughs in immunotherapy for head and neck cancers. (PubMed, Curr Opin Oncol)
    Recent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Erbitux (cetuximab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Bavencio (avelumab) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Padcev (enfortumab vedotin-ejfv) • Meiyouheng (becotatug vedotin) • ficerafusp alfa (BCA101) • petosemtamab (MCLA-158) • becotarug (JMT101) • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • Cotelet (tagitanlimab)
    2ms
    A prospective, single-arm, phase II clinical trial of sacituzumab tirumotecan (SKB264) in combination with tagitanlimab (KL-A167) as second-line therapy for immune-resistant extensive-stage small cell lung cancer (ES-SCLC) (ChiCTR2500111691)
    P2, N=40, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital (Shandong Provincial Institute of Cancer Prevention and Treatment, Shandong Provincial Ca
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    2ms
    ST-A-TN: Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • albumin-bound paclitaxel • Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    5ms
    OptiTROP-Breast05: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer (clinicaltrials.gov)
    P2, N=175, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Sep 2027 | Trial primary completion date: Apr 2025 --> Sep 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    5ms
    SKB315-I-01: A Study of SKB315 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=246, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Feb 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    capecitabine • Cotelet (tagitanlimab) • SKB315
    5ms
    SKB264 combined with KL-A167 neoadjuvant therapy for early-stage, high-risk ER+/HER2- breast cancer (ChiCTR2500108090)
    P2, N=55, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    7ms
    Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) (clinicaltrials.gov)
    P2, N=28, Recruiting, Tianjin Medical University Second Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    7ms
    Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    8ms
    NeoSaciA: SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=55, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)
    8ms
    A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)